drugset / Trial / NCT05283954
Use of a Combined Regimen of Fluoxetine, Prednisolone and Ivermectin in the Treatment of Mild COVID-19 to Prevent Disease Progression Progression in Papua New Guinea
Phase 2/3
Withdrawn
Oriol Mitja
Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · collabNational Department of Health, Papua New Guinea · collab
RandomizedParallel-groupDouble-blindTreatment
Summary
The Fluo-Pred-Iver clinical trial will test the efficacy of a combined regimen of Fluoxetine, Prednisolone and Ivermectin (Fluo-Pred-Iver), as treatment for ambulatory patients with mild COVID-19. The overarching idea of the work proposed herein is to investigate the use of Fluo-Pred-Iver to treat COVID-19, conducting a randomized controlled clinical trial to evaluate a new indication for these widely available drugs. It is estimated to include 954 participants.
Timeline
- Start
- 2022-05-01
- Primary completion
- 2022-06-30
- Completion
- 2022-07-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Albendazole | Small molecule | 200 mg | Oral |
| Subject | Fluoxetine | Small molecule | 20 mg | Oral |
| Subject | Ivermectin | Small molecule | 0.4 mg/kg | Oral |
| Subject | Prednisolone | Other / unclassified | 25 mg | Oral |
| Subject | Vitamin C | Other / unclassified | 0.13 mg/kg | Oral |
| Subject | Vitamin C | Other / unclassified | 50 mg | Oral |